Heat shock proteins and cancer immunotherapy.
Vaccination with heat shock proteins from tumor have been shown to elicit an anti-tumor response. Current studies indicate that the immunogenicity of HSPs is derived from the antigenic peptides which they associate with. Mechanisms by which the HSP-peptide complexes induce an immune response and the possible role of HSPs in antigen presentation is discussed in this article. The use of HSP-peptide complexes can be used as tumor vaccines for cancer immunotherapy is reviewed.
Wang
X Y
XY
Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Kaneko
Y
Y
Repasky
E
E
Subjeck
J R
JR
D000818:Animals; D017951:Antigen Presentation; D019496:Cancer Vaccines / Q000627:therapeutic use; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D018832:Molecular Chaperones / Q000276:immunology; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011485:Protein Binding / Q000276:immunology
D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D018832:Molecular Chaperones; D009363:Neoplasm Proteins